Introduction

Combined drug sales in the five major European markets represent the second-biggest market globally after the US. Unlike the US, which is dominated by a wide range of private payers, governments are the major payers in Europe. The monopsonistic nature of these markets provides governments with significant leverage and they use extensive P&R controls to contain spiralling healthcare costs.

Scope

*Evaluation of the pressures facing the drugs industry and how these pressures will impact P&R

*Overview of global P&R controls, examining which are important in the European market both currently and in the future

*In-depth analysis of each of the five major European markets, examining both the healthcare systems and the key P&R infrastructure

*Identification of trends and recommendations shaping the European P&R environment

Highlights

Better dialogue between healthcare providers and drugs companies is vital; however, healthcare provider devolution has led to fragmentation of the key European markets, making it difficult to identify key P&R stakeholders

Many European governments profess to be willing to reward innovative drugs, however this is largely a smokescreen as debt-ridden governmental payers increasingly prioritize cost containment

European drug developers need to prioritize P&R as an important factor in drug development, and focus on securing strong P&R justification before green-lighting me-too drugs

Reasons to Purchase

*Gain a clear understanding of the healthcare market dynamics and P&R environment within each of the five major European healthcare markets

*Review P&R trends in Europe, based on Datamonitor's analysis and primary research conducted with key stakeholders in the industry

*Gain insight into how P&R fits into company strategy and understand how specific P&R trends are shaping the European markets

Introduction



Combined drug sales in the five major European markets represent the second-biggest market globally after the US. Unlike the US, which is dominated by a wide range of private payers, governments are the major payers in Europe. The monopsonistic nature of these markets provides governments with significant leverage and they use extensive P&R controls to contain spiralling healthcare costs.



Scope



*Evaluation of the pressures facing the drugs industry and how these pressures will impact P&R

*Overview of global P&R controls, examining which are important in the European market both currently and in the future

*In-depth analysis of each of the five major European markets, examining both the healthcare systems and the key P&R infrastructure

*Identification of trends and recommendations shaping the European P&R environment



Highlights



Better dialogue between healthcare providers and drugs companies is vital; however, healthcare provider devolution has led to fragmentation of the key European markets, making it difficult to identify key P&R stakeholders



Many European governments profess to be willing to reward innovative drugs, however this is largely a smokescreen as debt-ridden governmental payers increasingly prioritize cost containment



European drug developers need to prioritize P&R as an important factor in drug development, and focus on securing strong P&R justification before green-lighting me-too drugs



Reasons to Purchase



*Gain a clear understanding of the healthcare market dynamics and P&R environment within each of the five major European healthcare markets

*Review P&R trends in Europe, based on Datamonitor's analysis and primary research conducted with key stakeholders in the industry

*Gain insight into how P&R fits into company strategy and understand how specific P&R trends are shaping the European markets